Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Everspin, MaxLinear sign MOU to evaluate next-generation memory architectures for AI servers

Everspin, MaxLinear sign MOU to evaluate next-generation memory architectures for AI servers

ReutersReuters2026/08/04 11:07
  • Everspin signed an MOU with MaxLinear to evaluate next-generation memory architectures aimed at boosting efficiency in AI servers.
  • Work pairs Everspin’s persistent, low-latency MRAM with MaxLinear’s storage compression, encryption, and hardware acceleration platform.
  • Focus areas include metadata management, log data, write buffering, and cache functions to improve responsiveness, reliability, and data persistence.
  • Companies also plan joint market development targeting hyperscale cloud, AI infrastructure, and enterprise server customers.
  • MOU includes talks on long-term manufacturing, supply, and commercialization opportunities.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Everspin Technologies Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260804125095) on August 04, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage

Eli Lilly stated on Monday that its oral weight-loss drug, Foundayo, has captured over 30% of the market share among new patients in the US oral obesity treatment market, narrowing the early lead achieved by Danish competitor Novo Nordisk with its Wegovy oral tablets.

智通财经2026/09/15 03:21
Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage